Savita K. Sharma

Savita K. Sharma

Auto-generated profile, based on publicly available information

Savita K. Sharma

Chemistry Department Johns Hopkins University Baltimore MD 21218 USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2016 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
ACAmanda R. Corcos
Amanda R. Corcos
OVOmar Villanueva
Omar Villanueva
RWRichard C. Walroth
Richard C. Walroth
SSSavita K. Sharma
Savita K. Sharma
JBJohn Bacsa
John Bacsa
JBJohn F. Berry
John F. Berry

8 January 2020 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
HKHyun Kim
Hyun Kim
PRPatrick J. Rogler
Patrick J. Rogler
SSSavita K. Sharma
Savita K. Sharma
ASAndrew W. Schaefer
Andrew W. Schaefer
Edward SolomonEdward Solomon
Edward Solomon
KKKenneth D. Karlin
Kenneth D. Karlin

1 November 2017 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
SSSavita K. Sharma
Savita K. Sharma
ASAndrew W. Schaefer
Andrew W. Schaefer
HLHyeongtaek Lim
Hyeongtaek Lim
HMHirotoshi Matsumura
Hirotoshi Matsumura
PMPierre Moenne-Loccoz
Pierre Moenne-Loccoz
KKKenneth D. Karlin
Kenneth D. Karlin

22 October 2013 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
IGIsaac Garcia-Bosch
Isaac Garcia-Bosch
SSSavita K. Sharma
Savita K. Sharma
KKKenneth D. Karlin
Kenneth D. Karlin

28 December 2016 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
SASuzanne M. Adam
Suzanne M. Adam
IGIsaac Garcia-Bosch
Isaac Garcia-Bosch
ASAndrew W. Schaefer
Andrew W. Schaefer
SSSavita K. Sharma
Savita K. Sharma
MSMaxime A. Siegler
Maxime A. Siegler
KKKenneth D. Karlin
Kenneth D. Karlin

7 January 2020 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
YTYesim A Tahirovic
Yesim A Tahirovic
SPSameshnee Pelly
Sameshnee Pelly
EJEdgars Jecs
Edgars Jecs
EMEric J Miller
Eric J Miller
SSSavita K Sharma
Savita K Sharma
LWLawrence J Wilson
Lawrence J Wilson
Introduction: The chemokine receptor CXCR4 has been under intense study due to the central role it plays in immune system regulation and the pathology of many human diseases. The FDA approval of the first CXCR4 antagonist drug Plerixafor (i.e., AMD3100, Mozobil®) ushered in an increase in patent activity covering CXCR4 based therapeutic agents over the past decade. Areas covered: This article describes patent documents published during the period of 2010 through 2018 for both small molecules and peptide-based CXCR4 modulators as therapeutic agents. There is an expansion of intellectual property (IP) around existing and new small molecules of clinical interest, including new chemotypes featuring aromatic and aliphatic heterocycles. There is also significant IP covering peptide-based therapeutics, although about half as many in number as those covering small molecules. Expert opinion: In the last decade there has been significant interest in modulators of the CXCR4 receptor, as gauged by the number of patent filings and clinical investigations targeting this receptor for human disease intervention. Seven of the many CXCR4 modulators described herein, that are currently in human clinical trials, are likely to spur the creation of other FDA approved therapeutics in the near future, most likely as immune and oncology drugs.